FORTREA HOLDINGS INC.
NASDAQ: FTRE (Fortrea Holdings Inc.)
Last update: 1 hour ago14.53
2.28 (18.61%)
| Previous Close | 12.25 |
| Open | 13.96 |
| Volume | 4,227,911 |
| Avg. Volume (3M) | 1,613,426 |
| Market Cap | 1,374,316,032 |
| Price / Earnings (Forward) | 7.13 |
| Price / Sales | 0.410 |
| Price / Book | 2.06 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Profit Margin | -29.43% |
| Operating Margin (TTM) | -3.81% |
| Diluted EPS (TTM) | -8.39 |
| Quarterly Revenue Growth (YOY) | -1.60% |
| Total Debt/Equity (MRQ) | 149.92% |
| Current Ratio (MRQ) | 0.970 |
| Operating Cash Flow (TTM) | 164.20 M |
| Levered Free Cash Flow (TTM) | 310.66 M |
| Return on Assets (TTM) | -1.74% |
| Return on Equity (TTM) | -61.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Fortrea Holdings Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.25 |
|
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.40% |
| % Held by Institutions | 101.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Park West Asset Management Llc | 31 Dec 2025 | 2,038,159 |
| Iron Triangle Partners Lp | 31 Dec 2025 | 1,986,333 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Baird, 10.12%) | Buy |
| Median | 15.00 (3.24%) | |
| Low | 12.00 (Barclays, -17.41%) | Hold |
| Average | 14.33 (-1.38%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 10.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| TD Cowen | 09 Mar 2026 | 15.00 (3.23%) | Buy | 9.83 |
| Baird | 27 Feb 2026 | 16.00 (10.12%) | Buy | 10.72 |
| Barclays | 27 Feb 2026 | 12.00 (-17.41%) | Hold | 10.72 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |